Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients.
Gian Carlo MattiucciLuca BoldriniAlessia NardangeliAndrea D'AvieroMilly BuwengeFrancesco CelliniFrancesco DeodatoNicola DinapoliVincenzo FrascinoGabriella MacchiaAlessio Giuseppe MorgantiVincenzo ValentiniPublished in: Journal of cancer research and clinical oncology (2020)
Treatment intensification with hypofractionated radiotherapy boost is well tolerated in pts affected by unresectable LAPC previously treated with CT/CRT. Its rates of local and pain control are encouraging, supporting its introduction in clinical practice. Timing, schedule and dose of HRB need to be further investigated to personalize therapy and optimize clinical advantages.
Keyphrases
- locally advanced
- radiation therapy
- neoadjuvant chemotherapy
- rectal cancer
- squamous cell carcinoma
- phase ii study
- clinical practice
- radiation induced
- chronic pain
- computed tomography
- image quality
- neuropathic pain
- pain management
- dual energy
- small cell lung cancer
- contrast enhanced
- brain metastases
- spinal cord injury
- magnetic resonance
- stem cells
- postoperative pain
- replacement therapy
- left ventricular